p16 INK4A, also designated as CDKN2A or p16, is an important cell cycle regulator and acts as a tumor suppressor that inhibits the catalytic activity of the Cdk4/cyclin D complex. P16 binds to CDK4 and inhibiting its kinase ability, so that it cannot phosphorylate the retinoblastoma tumor suppressor (RB). Mutations in the gene leads to inactivation of p16 protein which has been associated with an increased risk of cancer and are often observed in primary tumors and in cancer cell lines. Aberrant p16 INK4a have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas.
|Tissue Type/Cancer Type||
Squamous Carcinoma of Cervix Tissue
6 mL – Manual – RTU, 100 Tests – Automation – i6000, 1 mL – Manual – Concentrate, 0.5 mL – Manual – Concentrate, 50 Tests – Automation – Xmatrx, 50 tests – NanoVIP®, 160 Tests – Automation – Xmatrx, 5 slides – Xmatrx, 5 slides – Manual